Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | F2 | P00734 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | HPGDS | O60760 | 10/20 | 0.58 |
| ▸ | MGAM | O43451 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6085328 | 0.98 | ALDH1A1 (0.62) | ALDH1A1HPGDF2GLAKDM4E | |
| SCHEMBL4407431 | 0.88 | ALDH1A1 (0.68) | ALDH1A1HPGDF2GLAKDM4E | |
| SCHEMBL622114 | 0.88 | HPGDS (0.76) | KDM4EHPGDS | |
| SCHEMBL30504629 | 0.88 | HPGDS (0.76) | KDM4EHPGDS | |
| SCHEMBL18371227 | 0.88 | KDM4E (0.63) | ALDH1A1HPGDF2GLAKDM4E | |
| SCHEMBL3845152 | 0.86 | HPGDS (0.78) | ALDH1A1HPGDF2GLAKDM4E | |
| SCHEMBL20799517 | 0.86 | ALDH1A1 (0.62) | ALDH1A1HPGDF2GLAHPGDS | |
| Hydrochloric Acid SCHEMBL6085339 | 0.86 | HPGDS (0.74) | KDM4EHPGDS | |
| SCHEMBL4217798 | 0.85 | MGAM (0.54) | ALDH1A1HPGDF2GLAKDM4E | |
| SCHEMBL4145819 | 0.84 | ALDH1A1 (0.59) | ALDH1A1HPGDF2GLAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102633-B2 | Spirolactone compounds | QUIXGEN, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-3644998-B1 | NOVEL SPIROLACTONE COMPOUNDS | QUIXGEN INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230355609-A1 | Spirolactone Compounds | QUIXGEN, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| CN-110799187-B | Spirolactone compounds | 汇科锦公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11541046-B2 | Spirolactone compounds | QUIXGEN, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210145822-A1 | Novel Spirolactone Compounds | QUIXGEN, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3644998-A1 | NOVEL SPIROLACTONE COMPOUNDS | Quixgen, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| CN-110799187-A | Novel spirolactone compounds | 汇科锦公司 | 2020-02-14 | — | — | CN | disclosed |
| WO-2019006324-A1 | NOVEL SPIROLACTONE COMPOUNDS | QUIXGEN, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| CN-106117205-B | Pyrazolo spiral shell ketone derivatives as acetyl-CoA carboxylase inhibitor class | 辉瑞大药厂 | 2018-09-21 | — | — | CN | disclosed |
| US-6255490-B1 | TREATING DISORDERS ASSOCIATED WITH CHANGES IN CHOLINERGIC ACTIVITY; NON-OPIATE BASED ANALGESIC FOR MODERATE TO SEVERE PAIN EQUALLY OR EXCEEDING THE POTENCY OF OPIATE ANALGESICS, YET LACKING ADDICTIVE SIDE EFFECTS | UNIVERSITY OF VIRGINIA | 2001-07-03 | — | — | US | disclosed |
| WO-2000073283-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| US-6117889-A | 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents | UNIVERSITY OF VIRGINIA (US) | 2000-09-12 | — | — | US | disclosed |
| US-6060473-A | 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands | UCB S.A. - DTB (BE) | 2000-05-09 | — | — | US | disclosed |
| EP-0778835-A4 | 7-AZABICYCLO 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIV VIRGINIA (US) | 1999-02-03 | — | — | EP | disclosed |
| US-5817679-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | UNIVERSITY OF VIRGINIA (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0778835-A1 | 7-AZABICYCLO 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF VIRGINIA (US) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996006093-A1 | 7-AZABICYCLO[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF VIRGINIA (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0691971-A1 | 7-AZABICYCLO- 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS | UNIVERSITY OF VIRGINIA (US) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022868-A1 | 7-AZABICYCLO-[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS | UNIVERSITY OF VIRGINIA (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541046-B2 | Spirolactone compounds | ACACA, AKR1C2, AKR1A1 | ALDH1A1 40/4885HPGD 735/4885F2 3660/4885 |
| US-20210145822-A1 | Novel Spirolactone Compounds | ACACA, HSD17B10, AKR1C2 | ALDH1A1 43/4885HPGD 730/4885F2 3703/4885 |
| US-20230355609-A1 | Spirolactone Compounds | ACACA, AKR1C2, AKR1A1 | ALDH1A1 40/4885HPGD 735/4885F2 3660/4885 |
| US-12102633-B2 | Spirolactone compounds | ACACA, AKR1C2, AKR1A1 | ALDH1A1 40/4885HPGD 735/4885F2 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.